HC Wainwright & Co. maintains uniQure at Buy, lowers price target to $65 from $80

HC Wainwright & Co. kept uniQure's rating at Buy but reduced its price target from $80 to $65, an 18.8% cut. The new target suggests a 212.8% upside from the Nov 17 close of $20.78, according to the firm.

Original reporting
Published Nov 18, 2026, 12:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 12:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HC Wainwright & Co. maintains uniQure at Buy, lowers price target to $65 from $80 — source image
Decision brief

The 30-second read

$QUREBearishLow
01

Why it matters

Lowering the price target reduces the valuation benchmark used by some investors, which can weigh on sentiment even when the rating stays Buy.

02

Market read

This is a single-name valuation adjustment, likely affecting short-term sentiment more than fundamentals.

03

What to watch

The article provides no thesis details behind the target cut, so traders may need to check the underlying analyst rationale before assuming fundamental deterioration.

Relevance 4/10Novelty 4/10Timing: today (analyst note update)

Background

The piece is an analyst-research update: HC Wainwright keeps uniQure at Buy while lowering its price target.

Company-level read

Ticker impact

$QUREBearishMedium confidence
Context

HC Wainwright maintains uniQure at Buy but cuts its price target to $65 from $80, signaling a lower valuation despite the Buy rating.

Expected impact

Shares may face mild downside or underperformance as the market digests the lower target, unless other catalysts offset it.

Evidence & confidence

The article discloses only an analyst price-target reduction (no new company fundamentals). That typically affects sentiment and positioning more than fundamentals, so impact is likely limited but directionally negative.

Market effects

Limited read-through to gene therapy peers since this is a single-name target cut without new sector data.

No clear regional spillover implied by the article.

Minimal global relevance; this is a US analyst target update for a single company.

Counterpoint

A maintained Buy rating can still support dip-buying, especially if the market focuses on the implied upside rather than the reduced target.

Key entities

  • uniQure

    Gene therapy company referenced as the subject of the analyst rating and price-target change.

  • HC Wainwright & Co.

    Brokerage issuing the maintained Buy rating and reduced price target.

Related articles

$QUREMedAI 8/10

QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?

uniQure N.V. (QURE) shares rose 17.5% in a month, outperforming the industry and S&P 500. The rally was driven by FDA acceptance of its Huntington's disease drug application, ifezuntirgene inilparvovec, for review. Despite weaker Q3 2026 results, investors focus on the drug's potential. QURE's cash position is strong, with $768.4M as of Sept. 30, 2026, expected to fund operations through 2030.

$QUREMedAI 8/10

uniQure Prepares for Potential FDA Panel on Huntington’s Gene Therapy After Priority Review Nod

uniQure (QURE) is preparing for a potential FDA panel review of its gene therapy AMT-130 for Huntington's disease after receiving a priority review nod. The company presented 48-month data showing treated patients had less functional decline than untreated ones, though control group limitations were noted. uniQure plans a confirmatory study and is preparing for a potential launch, with $780 million in cash to fund operations into 2030.

$QUREHighAI 9/10

Key facts: AMT-130 Priority Review; 48-Month Data; Q3 Revenue +40%

uniQure's AMT-130 was accepted for FDA Priority Review with a decision goal of May 1, 2027. The U.K. validated its marketing application. 48-month data showed slowed Huntington’s disease progression. Q3 2026 revenue rose 40.4% to $5.2 million, below estimates, with net loss narrowing to $61.2 million. Cash reserves were $768.4 million.

MedAI 8/10

uniQure N.V. Q3 2026 Earnings Call Summary

uniQure N.V. reported that the FDA accepted its AMT-130 BLA with priority review for Huntington's disease, citing 36-month data showing a 60% slowing in TFC decline. The company plans a focused commercial launch targeting 15-30 priority institutions. Management expects the confirmatory study to be underway by the 2027 PDUFA date and cash runway to extend into 2030. SG&A expenses increased by $4.5 million year-over-year.

$QUREMed

uniQure (QURE) Q3 2026 Earnings Call Transcript

uniQure (QURE) reported progress in its Q3 2026 earnings call. The company's AMT-130 therapy for Huntington's disease showed a 75% slowing of disease progression in trials. The FDA is reviewing the Biologics License Application (BLA) with a PDUFA date of May 1, 2027. uniQure is preparing for a potential U.S. launch in 2027 and advancing its pipeline, including studies for AMT-260 and AMT-191. The company is also building its commercial teams ahead of the planned launch.